GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.

@article{Ahrn2004GLP1RA,
  title={GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.},
  author={Bo Ahr{\'e}n and Ole Schmitz},
  journal={Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme},
  year={2004},
  volume={36 11-12},
  pages={867-76}
}
Glucagon-like peptide-1 (GLP-1) is an incretin hormone with antidiabetic action through its ability to stimulate insulin secretion, increase beta cell neogenesis, inhibit beta cell apoptosis, inhibit glucagon secretion, delay gastric emptying and induce satiety. It has therefore been explored as a novel treatment of type 2 diabetes. A problem is, however, that GLP-1 is rapidly inactivated by the dipeptidyl peptidase-4 (DPP-4) enzyme, which results in a short circulating half-life of the active… CONTINUE READING